NK Cells in Myeloproliferative Neoplasms (MPN)
Myeloproliferative neoplasms (MPNs) comprise a heterogenous group of hematologic neoplasms which are divided into Philadelphia positive (Ph+), and Philadelphia negative (Ph−) or classical MPNs. A variety of immunological factors including inflammatory, as well as immunomodulatory processes, closely...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/17/4400 |
| _version_ | 1797521586030379008 |
|---|---|
| author | Erin Naismith Janine Steichen Sieghart Sopper Dominik Wolf |
| author_facet | Erin Naismith Janine Steichen Sieghart Sopper Dominik Wolf |
| author_sort | Erin Naismith |
| collection | DOAJ |
| description | Myeloproliferative neoplasms (MPNs) comprise a heterogenous group of hematologic neoplasms which are divided into Philadelphia positive (Ph+), and Philadelphia negative (Ph−) or classical MPNs. A variety of immunological factors including inflammatory, as well as immunomodulatory processes, closely interact with the disease phenotypes in MPNs. NK cells are important innate immune effectors and substantially contribute to tumor control. Changes to the absolute and proportionate numbers of NK cell, as well as phenotypical and functional alterations are seen in MPNs. In addition to the disease itself, a variety of therapeutic options in MPNs may modify NK cell characteristics. Reports of suppressive effects of MPN treatment strategies on NK cell activity have led to intensive investigations into the respective compounds, to elucidate the possible negative effects of MPN therapy on control of the leukemic clones. We hereby review the available literature on NK cells in Ph+ and Ph− MPNs and summarize today’s knowledge on disease-related alterations in this cell compartment with particular focus on known therapy-associated changes. Furthermore, we critically evaluate conflicting data with possible implications for future projects. We also aim to highlight the relevance of full NK cell functionality for disease control in MPNs and the importance of considering specific changes related to therapy in order to avoid suppressive effects on immune surveillance. |
| first_indexed | 2024-03-10T08:14:35Z |
| format | Article |
| id | doaj.art-68461002eb3a4f66aa4937dc965279d3 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T08:14:35Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-68461002eb3a4f66aa4937dc965279d32023-11-22T10:26:52ZengMDPI AGCancers2072-66942021-08-011317440010.3390/cancers13174400NK Cells in Myeloproliferative Neoplasms (MPN)Erin Naismith0Janine Steichen1Sieghart Sopper2Dominik Wolf3Internal Medicine V, Department of Haematology and Oncology, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, AustriaInternal Medicine V, Department of Haematology and Oncology, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, AustriaInternal Medicine V, Department of Haematology and Oncology, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, AustriaInternal Medicine V, Department of Haematology and Oncology, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, AustriaMyeloproliferative neoplasms (MPNs) comprise a heterogenous group of hematologic neoplasms which are divided into Philadelphia positive (Ph+), and Philadelphia negative (Ph−) or classical MPNs. A variety of immunological factors including inflammatory, as well as immunomodulatory processes, closely interact with the disease phenotypes in MPNs. NK cells are important innate immune effectors and substantially contribute to tumor control. Changes to the absolute and proportionate numbers of NK cell, as well as phenotypical and functional alterations are seen in MPNs. In addition to the disease itself, a variety of therapeutic options in MPNs may modify NK cell characteristics. Reports of suppressive effects of MPN treatment strategies on NK cell activity have led to intensive investigations into the respective compounds, to elucidate the possible negative effects of MPN therapy on control of the leukemic clones. We hereby review the available literature on NK cells in Ph+ and Ph− MPNs and summarize today’s knowledge on disease-related alterations in this cell compartment with particular focus on known therapy-associated changes. Furthermore, we critically evaluate conflicting data with possible implications for future projects. We also aim to highlight the relevance of full NK cell functionality for disease control in MPNs and the importance of considering specific changes related to therapy in order to avoid suppressive effects on immune surveillance.https://www.mdpi.com/2072-6694/13/17/4400Innate immunityCMLpolycythemia veraessential thrombocythemiaprimary myelofibrosis |
| spellingShingle | Erin Naismith Janine Steichen Sieghart Sopper Dominik Wolf NK Cells in Myeloproliferative Neoplasms (MPN) Cancers Innate immunity CML polycythemia vera essential thrombocythemia primary myelofibrosis |
| title | NK Cells in Myeloproliferative Neoplasms (MPN) |
| title_full | NK Cells in Myeloproliferative Neoplasms (MPN) |
| title_fullStr | NK Cells in Myeloproliferative Neoplasms (MPN) |
| title_full_unstemmed | NK Cells in Myeloproliferative Neoplasms (MPN) |
| title_short | NK Cells in Myeloproliferative Neoplasms (MPN) |
| title_sort | nk cells in myeloproliferative neoplasms mpn |
| topic | Innate immunity CML polycythemia vera essential thrombocythemia primary myelofibrosis |
| url | https://www.mdpi.com/2072-6694/13/17/4400 |
| work_keys_str_mv | AT erinnaismith nkcellsinmyeloproliferativeneoplasmsmpn AT janinesteichen nkcellsinmyeloproliferativeneoplasmsmpn AT sieghartsopper nkcellsinmyeloproliferativeneoplasmsmpn AT dominikwolf nkcellsinmyeloproliferativeneoplasmsmpn |